Access to Medicine
PhRMA and BIO request EU be added to USTR Watch List over review of incentives
PhRMA and BIO have both requested that the US Trade Representative place the European Union on its watch list in the 2018 Special 301 Report. The Special 301 Report is a yearly review by the US Trade Representative of the… Continue Reading
CAR-T
Gilead 10-Q, 3rd quarter 2017 If any party is successful in establishing exclusive rights to axi-cel, our anticipated revenues and earnings from the sale of that product could be adversely affected. In October 2017, we acquired Kite, which is now… Continue Reading
PhRMA’s 2018 Special 301 Submission targets Australia, Canada, S. Korea, Japan & others over pricing, reimbursement policies
In its 2018 Special 301 submission, PhRMA targets a number of countries for pricing and reimbursement policies deemed hostile to the pharmaceutical industry. Among these, PhRMA strategically lobbies for the strongest classifications for Canada and Korea — countries dealing with… Continue Reading
SCP 26
July 3 to July 6, 2017 WIPO’s Page for the Meeting SCP26 – Agreement reached on future work reached at WIPO Standing Committee on the Law of Patents (6 July 2017) WIPO SCP 26 KEI Side Event: Running royalties as… Continue Reading
Negotiations on R&D funding agreements
1994 1994: Pharmaceutical Drugs, Intellectual Property Rights and Public Health: A Consumer Perspective from the United States, May 12. A discussion of how R&D mandates can ensure innovation does not suffer when prices lowering policies are embraced. 1996 1996: Comments… Continue Reading
Competition
USDOJ 2017 UPDATE OF THE ANTITRUST GUIDELINES FOR THE LICENSING OF INTELLECTUAL PROPERTY STANDARD SETTING AND COMPETITION November 8, 2012 COMPETITION, INNOVATION AND INTELLECTUAL PROPERTY, April 26, 2012 CHAPTER 6 : COMPETITIVE ISSUES REGARDING PRACTICES THAT EXTEND THE MARKET POWER… Continue Reading
Legislation on transparency of R&D costs in biopharmaceutical sector
This page features KEI blog posts, testimony, comments, and research on the transparency of the costs of research and development in the pharmaceutical sector. United States Transparency Legislation 16 March 2017: KEI testifies before a Maryland House of Delegates Subcommittee… Continue Reading
KEI Reaction to the White House CEA Paper on Biopharmaceutical Pricing Home and Abroad
On February 9, 2018, the Trump Administration released a paper by the Counsel of Economic Advisers (CEA) on drug pricing. The paper on pricing was thought to have been led by economist Tomas Philipson, appointed to the CEA by President… Continue Reading
KEI Comments to USTR regarding 2018 Special 301 list
